Upstream Bio (UPB) Net Cash Flow (2023 - 2026)

Upstream Bio's Net Cash Flow history runs 4 years deep, the most recent figure standing at -$4.9 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 98.09% year-over-year to -$4.9 million; the TTM figure through Mar 2026 stood at $25.4 million (down 36.46% YoY), while the FY2025 annual figure was -$224.3 million, down 174.71% from the prior year.
• Net Cash Flow was -$4.9 million for Q1 2026 at Upstream Bio, down from $29.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $292.9 million in Q4 2024 to a low of -$254.6 million in Q1 2025.
• Historically, Net Cash Flow has averaged $5.0 million across 4 years, with a median of $411500.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow soared 1463.48% in 2024, then tumbled 4584.41% in 2025.
• A 4-year view of Net Cash Flow shows it stood at -$21.5 million in 2023, then jumped by 1463.48% to $292.9 million in 2024, then slumped by 89.96% to $29.4 million in 2025, then sank by 116.5% to -$4.9 million in 2026.
• The last three Net Cash Flow figures came in at -$4.9 million (Q1 2026), $29.4 million (Q4 2025), and $26.7 million (Q3 2025), per Business Quant data.